Metsera, Inc. MTSR 深 沪
已收盘 11-13 16:00:00 美东时间
70.50
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 70.50
- 总市值 0
- 52周最高 74.415
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 12.30
- 委 比 0.00%
- 总股本 --
- 历史最高 74.415
- 量 比 0
- 振 幅 0.00%
- 历史最低 12.30
- 每 手 1
- 风险率 11.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts
Pfizer previews 2026 guidance with earnings below consensus, softer sales outlook, COVID decline and LOE headwinds offset by pipeline growth.
2025-12-16 22:28
Ozempic Maker Novo Nordisk Faces Board Shakeup
Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market.
2025-11-14 22:12
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India
Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.
2025-11-12 04:16
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Viasat Inc (NASDAQ:VSAT) rose sharply in pre-market trading after the...
2025-11-10 17:51
'Pfizer mulls suing Metsera, Novo over topping bid'- Semafor
https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid
2025-10-31 01:38
辉瑞公司即将以73亿美元收购减肥药生产商Metsera
辉瑞公司（PFE）早盘上涨2.1%。据悉，辉瑞公司即将以73亿美元收购减肥药生产商Metsera（MTSR）。该交易对Metsera的估值为每股47.50美元，另有22.50美元与业绩里程碑挂钩，较其最新收盘价溢价42.5%。此次收购符合辉瑞在不断增长的减肥药市场中扩大产品组合的战略。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-22 23:06
美股前瞻 | 三大股指期货齐跌，金价再创纪录，本周美联储官员讲话将成市场焦点
1. 9月22日(周一)美股盘前，美股三大股指期货齐跌。截至发稿，道指期货跌0.30%，标普500指数期货跌0.26%，纳指期货跌0.32%。 2. 截...
2025-09-22 19:54
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Metsera Inc.'s CEO, Whit Bernard, will present at the Goldman Sachs Global Healthcare Conference on June 11. The presentation will be webcast live and available for replay on Metsera's website.
2025-06-10 11:00
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
<p>Metsera, Inc. announced successful Phase 1 results forMET-233i, showing 8.4% weight loss, a 19-day half-life supporting monthly dosing, and no safety issues. Combination potential with MET-097i and ongoing trials were highlighted, with a conference call scheduled.</p>
2025-06-09 11:00
